MaxCyte Minutes Newsletter – Q2 2025

When funding is limited, every decision matters. Now more than ever, researchers need to show compelling results, reduce inefficiencies, and conserve valuable time and resources.

At MaxCyte, we understand what's at stake. We help scientific teams move quickly from concept to clinic with scalable, GMP-compliant solutions and unparalleled support. We help you get it right the first time and keep advancing with confidence.

In the news

See what true partnership looks like

Not all technology providers stay with you beyond the sale. At MaxCyte®, we do.

Our Strategic Platform License (SPL) isn’t just a contract—it’s the start of a hands-on, always-on partnership designed to support you from IND preparation through global manufacturing. From accelerating timelines to reducing cash burn, we’re with you at every stage of your therapeutic development.

We’ve updated our website to make it easier to see exactly what that journey looks like—and how our SPL model enables real, measurable outcomes.

SPL Graphics_three rings-pathway

Your pathway to development

The promise of autologous and allogeneic cell therapies

In Biocompare, James Brady, PhD, MBA, SVP of Technical Applications and Customer Support at MaxCyte, shares insights on factors shaping the choice between autologous and allogeneic therapies. “It often comes down to urgency, scalability and the immune profile of the disease,” he notes, emphasizing how therapy selection depends on treatment timelines, cost and patient-specific needs.

Technology Networks with Andrew Mancini

In his recent presentation during Technology Networks' Cell and Gene Therapy 2025 Symposium, MaxCyte’s Andrew Guy Mancini, PhD, explored the rapid evolution of engineered cell therapies, and what’s next for the field. From the rise of non-viral delivery methods to the shift toward allogeneic approaches, Dr. Mancini highlighted how developers are tackling complexity, scalability and cost to bring next-generation therapies to more patients.

Case study

Kamau logo

Investing in your success upfront

Learn how Kamau Therapeutics partnered with MaxCyte to optimize their cell engineering processes. Using MaxCyte’s GMP platform, they have advanced their lead program, nula-cel, currently in clinical development for sickle cell disease. Initially, the partnership focused on process development, culminating in a clinical collaboration announced in 2024.

quote-left
"Through our collaboration with MaxCyte and the use of their proven non-viral platform, our goal is to treat or cure a range of serious genetic diseases with unmet medical needs using homology-directed repair."
Matt Porteus, Co-Founder, Kamau Therapeutics, Inc.

Cell & gene therapy

UPCOMING WEBINAR

Combining CRISPR and Transposon-Based Technologies for Improved sdAb-Based CAR T Therapies

Tuesday, June 17, 2025 | 8:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Speakers
Begona Diez Cabezas headshot

Begoña Diez Cabezas
Researcher CIEMAT/CIBERER/IIS-
FJDager at CliniStem (GMP facility)

Juan Roberto Rodriguez-Madoz headshot

Juan Roberto Rodriguez-Madoz
Investigator Immune Therapies
Lab. Hematology Oncology-Program, Cima Universidad de Navarra

cell_and_gene_logo

Cell & Gene Tech Expo

We were pleased to take part in this important event dedicated to advancing quality and safety in cell therapy development. In case you missed these presentations hosted by Cell & Gene, they are now available on-demand.

GMP & Regulatory Compliance: Mitigate Clinical Risk in Your Cell Therapy Development with a GMP-compliant Process from the Get-Go

At this event, Sean Menarguez shared strategies to safeguard clinical success through the early adoption of GMP-compliant processes. In his presentation, Sean covered:

  • How early adoption of GMP-compliant processes can reduce downstream risks.
  • A collaborative approach to accelerating development timelines.
  • How MaxCyte can support your journey from research to commercialization.
Speaker
Sean Menarguez headshot

Sean Menarguez
Sr. Director of Global Business
Development at MaxCyte, Inc.

Cell Therapy Solutions: High-Efficiency Cell Engineering with MaxCyte's Electroporation Platform from Concept to Clinic

Dan Miller showcased how the MaxCyte electroporation platform is transforming high-efficiency cell engineering. Through his presentation, he highlighted our cutting-edge technology that accelerates the journey from concept to commercialization. We invite you to watch the presentation to learn how our platform enables streamlined, scalable and high-performance transfection across a wide range of cell types.
Speaker
Dan Miller

Dan Miller
Field Application Scientist
at MaxCyte, Inc.

Cell-based assays

UPCOMING WEBINAR

Cell-Based Screening:
Accelerating Therapeutic Development

Thursday, June 26, 2025 | 12:00 p.m. - 1:00 p.m. ET
Drug Discovery News text logo

Therapeutics development benefits substantially from physiologically relevant assays, ideally ones using disease-relevant cells or organoids. Cell-based assays in small-molecule drug discovery have traditionally relied on stable cell lines to deliver consistent assay performance at screening scale. However, stable cell line development can be costly and time consuming. For protein or cell-based immunotherapeutic discovery, phage display is considered the gold standard, but its long selection cycles and complex downstream development can create bottlenecks. In this webinar, James Brady will discuss an advanced transfection technology that enables the development of faster, more flexible cell-based screening assays.

In this webinar, you can discover how:

  • Streamlining assay development through increased speed and reproducibility
  • A faster, more adaptable alternative to traditional stable cell lines, transiently transfected assay ready cells
  • Accelerating antibody and cell therapy discovery with mammalian display screening
Speaker
James-Brady

James Brady
SVP of Technical Applications
and Customer Support at
MaxCyte, Inc.

Now available on-demand

Enabling Rapid Cell-Based Assay Development with Scalable Electroporation

This on-demand presentation includes a case study on high-throughput screening of ion channel variants using automated patch clamp recordings in assay ready cells. Researchers analyzed epilepsy-associated potassium channel variants (KCNQ2), using high-throughput assays to characterize previously unstudied variants and assess their responses to a candidate therapeutic. MaxCyte’s electroporation technology enabled the creation of assay ready cells, supporting ion channel variant analysis at an unprecedented scale.

Application note

A MaxCyte-Enabled Mammalian Display Method for the Development of Enhanced Affinity TCR-Based Biologics

Researchers at the University of Stuttgart and Immatics Biotechnologies developed a mammalian display platform to select affinity-enhanced TCR sequences expressed in a proprietary bispecific T cell engaging receptor format. MaxCyte electroporation technology enabled the generation of a mammalian display library used for candidate selection and the transient expression of soluble, bispecific T cell engaging receptors for functional characterization.

Figure 2: Visualization of membrane-anchored TCER.

Upcoming events

We are excited to attend multiple conferences and host many institutional seminars and events. Find all the latest on our events page.